Skip to main content
. Author manuscript; available in PMC: 2009 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2008 Sep;7(9):2725–2735. doi: 10.1158/1535-7163.MCT-08-0573

Figure 4.

Figure 4

Treatment of orthotopic E3LZ10.7 xenografts with IPI-269609. A, treatment with IPI-269609 (20 mg/kg/d p.o.) for 30 d did not affect the growth of orthotopic E3LZ10.7 xenografts. B, H&E stainings of orthotopic E3LZ10.7 treated with IPI-269609 (i) or solvent only (ii ). C, examples of histologies of E3LZ10.7 metastases to lymph node (i) and spleen (ii ); H&E staining.